Structure Therapeutics (GPCR) Stock: Buy, Sell, or Hold?
GPCR - Structure Therapeutics Inc. American Depositary Shares
$28.98
-2.29 (-7.32%)
▼
5d:
-19.54%
30d:
-38.51%
90d:
-45.78%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GPCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GPCR is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GPCR is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GPCR is currently trading at $28.98, which is considered oversold relative to its 30-day fair value range of $34.26 to $46.65.
Technical Outlook: Technically, GPCR is showing sideways momentum. The price is currently testing key support at $28.93. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: GPCR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $105.78 (+265.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GPCR is showing sideways momentum. The price is currently testing key support at $28.93. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: GPCR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $105.78 (+265.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$34.26 -
$46.65
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.3%)
- BULLISH: Trading 265.0% below Wall St target ($105.78)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$34.26 -
$46.65
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$28.93
Resistance Level
$37.74
Current Trend
Sideways
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.26
Wall Street Target
$105.78
(+265.0%)
Share & Embed Analysis
Last updated: October 02, 2026 5:47 AM ET
Data refreshes hourly during market hours. Next update: 6:47 AM
Data refreshes hourly during market hours. Next update: 6:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GPCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 68 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 63 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 69 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 60 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
